Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis in convenient administration forms.
With two unique projects, both developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.
Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.
Investor Relations contact
Carl-Magnus Högerkorp, interim CEO